Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Until now, HNSCC are treated with surgical removal of cancer tissue in primary region and lymph nodes combined with radiotherapy, cytostatic drugs and in some cases, epidermal growth factor receptor (EGFR) targeted antibody cetuximab and programmed death receptor-1 (PD-1) antibodies.
|
31785230 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Several growth factors and their receptors, such as epidermal growth factor receptor, have been studied as prognostic biomarkers for many epithelial malignancies.
|
31062130 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, we demonstrate that chemical inhibitors targeting specific KMTs and KDMs are able to promote or block extrachromosomal EGFR amplification, which identifies potential therapeutic strategies for controlling EGFR copy number heterogeneity in cancer, and in turn, drug response.
|
31776131 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, proposed benzothiazole derivatives may be promising EGFR tyrosine kinase inhibitors for potential application as cancer therapy.Communicated by Ramaswamy H. Sarma.
|
30955452 |
2020 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Patients with early-stage cancer and EGFR mutations who's neutrophils-to-lymphocytes rate (NLR) could be prognostic factor to evaluate efficacy.
|
31721468 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
EGFR is a clinically approved drug target in cancer.
|
30727906 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Epidermal growth factor receptor (EGFR) and MEK inhibitors (EGFR/MEKi) are beneficial for the treatment of solid cancers but are frequently associated with severe therapy-limiting acneiform skin toxicities.
|
31805013 |
2020 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To investigate its therapeutic availability in cancer therapy, we here modified the hybrid system to stably express EGFR shRNA and confirmed the antitumor effects.
|
31786264 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Unlike mucin-shielded normal bladder cells, cancer cells are exposed to the bladder lumen and overexpress EGFR.
|
31584195 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Due to its frequent overexpression and hyperactivation, EGFR has been a therapeutic target for human malignancies.
|
31639425 |
2020 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Docking analysis and molecular dynamics (MD) simulations were performed to understand the plausible structural and dynamical implications caused by somatic mutations available in the Catalogue of Somatic Mutations in Cancer database on the EGFR and anti-EGFR mAbs.
|
31228284 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Inhibition of angiogenesis with consequent impairments in intratumoral microcirculation is one of the mechanisms through which EGFR inhibition halts the progression of cancer.
|
31778239 |
2020 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The single nucleotide polymorphisms (SNPs) of microRNA-binding sites with target genes in the EGFR pathway could lead to alteration in the combination of microRNA with target genes and contribute to the susceptibility of cancer.
|
31269493 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our study suggests that EGFR plays an important role in the development of cancer stem cells by stabilizing SOX2.
|
31823521 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
EGFR) families, is an approved treatment for B cell malignancies.
|
31582534 |
2020 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Transcriptionally Active HPV and Targetable EGFR Mutations in Sinonasal Inverted Papilloma: An Association Between Low-risk HPV, Condylomatous Morphology, and Cancer Risk?
|
31743131 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Activation of epidermal growth factor receptor (EGFR) has been reported in a variety of cancer types, including colorectal cancer (CRC), and represents a potential chemotherapeutic drug target.
|
31308698 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Smart nanoparticles assembled by endogenous molecules for siRNA delivery and cancer therapy via CD44 and EGFR dual-targeting.
|
30352311 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals.
|
31019378 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> This study evaluates the cytotoxicity of AuNPs coated with polyallylamine (AuNPs-PAA) and conjugated or not to the epidermal growth factor receptor (EGFR)-targeting antibody Cetuximab (AuNPs-PAA-Ctxb) in normal human kidney (HK-2), liver (THLE-2) and microvascular endothelial (TIME) cells, and compares it with two cancer cell lines that are EGFR-overexpressing (A431) or EGFR-negative (MDA-MB-453).
|
31371943 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Despite the latest advancements in cancer diagnostics and therapeutics against EGFR, the survival rates of patients with advanced head and neck cancer remain disappointing due to anti-EGFR resistance.
|
30700700 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
EGFR inhibitors from cancer to inflammation: Discovery of 4-fluoro-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide as a novel anti-inflammatory EGFR inhibitor.
|
30685642 |
2019 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.
|
30610926 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Epidermal Growth Factor Receptor (EGFR) signaling to the Ras-MAPK pathway is implicated in the development and progression of cancer and is a major focus of targeted combination therapies.
|
28113516 |
2019 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this article we reviewed how biotransformation of ingested arsenic may lead to cancer by modulating the activation of several essential signalling pathways such as EGFR, PI3K/AKT, RTK/Ras/PI3K, JNK/STAT3 and Nrf2-KEAP1; by producing epigenetics modifications and by disrupting normal expression of miRNAs.
|
30878179 |
2019 |